Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal mot...
Truist Securities analyst Joon Lee maintains argenx (NASDAQ:ARGX) with a Buy and raises the price target from $440 to $480.
The FDA has approved Argenx's Vyvgart Hytrulo for chronic inflammatory demyelinating polyneuropathy, with projections of $1...
B of A Securities analyst Tazeen Ahmad reiterates argenx (NASDAQ:ARGX) with a Buy and raises the price target from $535 to $...
Stifel analyst Alex Thompson maintains argenx (NASDAQ:ARGX) with a Buy and raises the price target from $485 to $500.
Piper Sandler analyst Allison Bratzel maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $522...
VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating pol...
